Patent classifications
A61L27/50
SYSTEMS AND METHODS PRODUCING SEEDED GRAFTS
Closed disposable seeding systems with improved seeding chambers permitting uniform seeding of a scaffold or graft with patient's cells are provided. The seeding chambers with a variable width along the length of the chamber, or a minimal gap between the scaffold and chamber wall, provide an improvement of the prior seeding chambers of closed disposable seeding systems by providing faster and more efficient and uniform seeding of the grafts and scaffolds. Also described are scaffolds with biomechanical and structural properties permitting spontaneous reversal of stenosis and neotissue formation as the graft degrades yielding a scaffold-free neovessel.
Therapy for post-traumatic osteoarthritis
Compositions comprising a reverse-temperature sensitive hydrogel comprising a biopolymer such as a polysaccharide and a synthetic polymer, and a compound in an amount that reversibly inhibits respiratory enzyme complex I, and methods of using the composition, are provided.
Therapy for post-traumatic osteoarthritis
Compositions comprising a reverse-temperature sensitive hydrogel comprising a biopolymer such as a polysaccharide and a synthetic polymer, and a compound in an amount that reversibly inhibits respiratory enzyme complex I, and methods of using the composition, are provided.
Method of corneal transplantation or corneal inlay implantation with cross-linking
A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) prior to implantation, treating an implant formed from donor corneal tissue or a tissue culture grown corneal stroma with a solution of sodium dodecyl sulfate (SDS), Triton X-100, benzalkonium chloride (BAK), Igepal, genipin, 100% glycerol, or alcohol for making the implant acellular, and for killing any bacteria, viruses, or parasites prior to implantation; (ii) implanting the implant into a recipient cornea; (iii) applying laser energy to the implant so as to modify the refractive power of the implant while being monitored using a Shack-Hartmann wavefront system so as to achieve a desired refractive power for the implant; and (iv) applying a cross-linking solution and irradiating the implant to cross-link the implant to prevent an immune response to the implant and/or rejection of the implant by a patient.
Method of corneal transplantation or corneal inlay implantation with cross-linking
A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) prior to implantation, treating an implant formed from donor corneal tissue or a tissue culture grown corneal stroma with a solution of sodium dodecyl sulfate (SDS), Triton X-100, benzalkonium chloride (BAK), Igepal, genipin, 100% glycerol, or alcohol for making the implant acellular, and for killing any bacteria, viruses, or parasites prior to implantation; (ii) implanting the implant into a recipient cornea; (iii) applying laser energy to the implant so as to modify the refractive power of the implant while being monitored using a Shack-Hartmann wavefront system so as to achieve a desired refractive power for the implant; and (iv) applying a cross-linking solution and irradiating the implant to cross-link the implant to prevent an immune response to the implant and/or rejection of the implant by a patient.
EXTRACELLULAR MATRIX STRUCTURES
A sheet structure comprising two joined extracellular matrix (ECM) tissue or sheet layers and a physiological sensor disposed therebetween; the ECM tissue being derived from a mammalian tissue source that includes small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), urinary basement membrane (UBM), liver basement membrane (LBM), amniotic membrane, mesothelial tissue, placental tissue and cardiac tissue.
EXTRACELLULAR MATRIX STRUCTURES
A sheet structure comprising two joined extracellular matrix (ECM) tissue or sheet layers and a physiological sensor disposed therebetween; the ECM tissue being derived from a mammalian tissue source that includes small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), urinary basement membrane (UBM), liver basement membrane (LBM), amniotic membrane, mesothelial tissue, placental tissue and cardiac tissue.
SPATIOTEMPORAL DELIVERY SYSTEM EMBEDDED IN 3D-PRINTING
Provided herein is a 3D printing system and related compositions, and method of using such, that can produce a polymeric microfiber having embedded microspheres encapsulating an active agent with micron precision and high spatial and temporal resolution.
SPATIOTEMPORAL DELIVERY SYSTEM EMBEDDED IN 3D-PRINTING
Provided herein is a 3D printing system and related compositions, and method of using such, that can produce a polymeric microfiber having embedded microspheres encapsulating an active agent with micron precision and high spatial and temporal resolution.
FETAL DECELLULARIZED NUCLEUS PULPOSUS MATERIAL AND METHODS FOR OBTAINING PHARMACEUTIC COMPOSITIONS TO BE USED IN THE TREATMENT OF INTERVERTEBRAL DISC DEGENERATION AND BACK PAIN
A fetal-origin decellularized nucleus pulposus (NP) allogenic material to regenerate a host's Intervertebral Disc (IVD). The decellularized NP material, obtained from a vertebrate fetus and characterized by comprising high levels of collagen 12 and 14, is used in a pharmacological composition for the treatment of IVD degeneration. The advance is based on the increased ability of the fetal decellularized NP material to stimulate the host constituent cell's to increase the expression of collagen 2 and aggrecan, promoting intrinsic IVD regeneration. A related method includes preparing the pharmaceutical compositions of fetal decellularized material in the form of fragments/microparticles and hydrogel for an injectable mode of administration. The involved material, pharmaceutical compositions and methods may be advantageously used for the prevention and treatment of IVD degeneration and back pain in human and veterinary settings.